Sanofi India Ltd vs Smruthi Organics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3407 as of 30 Apr 15:30 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Smruthi Organics Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Smruthi Organics Ltd is ₹ 0 crore as of December 2023 . The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Smruthi Organics Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Smruthi Organics Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Smruthi Organics Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Smruthi Organics Ltd changed from 20.08 % to 48.24 % over 5 quarters. This represents a CAGR of 101.61% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Smruthi Organics Ltd

Smruthi Organics Limited was incorporated in July, 1989 as a Private Limited Company and was subsequently converted into a Public Limited Company in February, 1995.
The Company was promoted by E Purushotham and Shankarrao R Myakal.
The Company is a manufacturer of Active Pharmaceutical Ingredient (API) products in the Anti - Diabetic, Anti - Hypertension and Anti - Infectives Therapeutic categories catering to both the Indian domestic as well as rest of the world (ROW) markets, with clients spanning across Asia, Americas, and Africa.
It has 2 manufacturing facilities in Solapur, India. The Company set up a plant at Solapur, Maharashtra, to manufacture bulk drugs like diloxanide furoate (inst. cap. : 24 tpa) and sulphadiazine (inst. cap. : 36 tpa).
It expanded its activities and product range in 1993-94 by manufacturing metronidazole benzoate, tinidazole, paracetamol and norfloxacin.

FAQs for the comparison of Sanofi India Ltd and Smruthi Organics Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Smruthi Organics Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Smruthi Organics Ltd is 131 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Smruthi Organics Ltd?

The stock performance of Sanofi India Ltd and Smruthi Organics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Smruthi Organics Ltd?

As of May 4, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Smruthi Organics Ltd stock price is INR ₹114.85.

How do dividend payouts of Sanofi India Ltd and Smruthi Organics Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Smruthi Organics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.